1 Process to Address Specifications for Delivered Dose Uniformity of Inhaled and Nasal Drug Products Presented by Robert O’Neill, Ph.D. Chair ACPS Working.

Slides:

Advertisements

Similar presentations

Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.

Advertisements

MAIN COMMITTEE OFFICERS DUTIES AND RESPONSIBILITIES.

Presented by Bo Olsson (AstraZeneca)

Program Management Office (PMO) Design

ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.

PhD PROPOSAL AND SUPERVISORY AGREEMENT FORM

The Statisticians Role in Pharmaceutical Development

Parametric Tolerance Interval (PTI) Test for Delivered Dose Uniformity (DDU) for Orally Inhaled and Nasal Drug Products (OINDP) Michael Golden On behalf.

1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,

Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.

Pharmaceutical Nomenclature Issues and challenges Moheb M. Nasr, Ph.D. Acting Director Office of New Drug Chemistry (ONDC) OPS, CDER, FDA Advisory Committee.

PROCESS AND PRODUCT QUALITY ASSURANCE

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

Pharmaceutical Product Quality Assurance Through CMC Drug Development Process Presented by Darlene Rosario (Aradigm) 21 October 2003 Meeting of the Advisory.

FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.

COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.

Individual Bioequivalence Lawrence J. Lesko, Ph.D. Director Office of Clinical Pharmacology and Biopharmaceutics Advisory Committee for Pharmaceutical.

Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue and Gene Therapies Web Seminar Series presents:

FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.

Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.

Organizational Gaps in Reaching the “Desired State” Helen Winkle.

Class of 2013 Fellows May 20, 2013 Sheraton Boston Hotel Boston, MA USA.

ITFG/IPAC Collaboration CMC Specifications Technical Team ITFG/IPAC TECHNICAL TEAM: CMC SPECIFICATIONS Presented by: Bo Olsson, PhD 26 April 2000 Rockville,

Physiologists & the FDA Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary.

Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.

1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Welcome and Introduction to the Meeting.

2015 MBSW1 Quality Assurance Test of Delivered Dose Uniformity of Multi-dose Spray and Inhalation Drug Products Drs. Yi Tsong 1, Xiaoyu (Cassie) Dong*

Respiratory Safety Pharmacology Endpoints in Toxicology Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North.

ACPS Meeting, October 19-20, 2004 BioINequivalence: Concept and Definition Lawrence X. Yu, Ph. D. Director for Science Office of Generic Drugs, OPS, CDER,

Research Peer-Review at CDER Past and Present Jerry M. Collins, Ph.D. Director, Laboratory of Clinical Pharmacology, OTR Acting Director, Division of Applied.

CPTR Overview CPTR 2012 Workshop October 2-4, 2012.

Parametric Tolerance Interval Test for Delivered Dose Uniformity (DDU) Working Group Update Moheb M. Nasr, Ph.D. Office of New Quality Assessment (ONDQA,

Bioequivalence Studies and Other Recommendations for Orally Inhaled and Nasal Drug Products: Work of the ITFG/IPAC-RS Collaboration Presented by Cynthia.

SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Overview of FDA's Regulatory Framework for PET Drugs

1 Basis of the Proposed Tactical Plan for a QbD approach for Quality Control and Assurance of Dissolution Rate Ajaz S. Hussain, Ph.D. Deputy Director,

1 U.S. Food and Drug Administration International Programs Melinda K. Plaisier Assistant Commissioner for International Programs U.S. Food and Drug Administration.

Meiyu Shen, PhD Collaborators: Xiaoyu Dong, Ph.D., Yi Tsong, PhD

COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.

Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview

DESIGNING A PROGRAM FOR REVIEW OF CDER LABORATORY RESEARCHERS Keith Webber, Ph.D. Acting Deputy Director OPS/CDER/FDA.

Executive Board Meeting October 14, 2009 Washington DC Role of the ICP Executive Board Michel Mouyelo-Katoula Global Manager International Comparison Program.

Guidance Update: Average, Population, and Individual Approaches to Establishing Bioequivalence Mei-Ling Chen, Ph.D. Associate Director Office of Pharmaceutical.

ROAD MAP: Getting a Cancer Study Done at Jefferson Sylvia O’Neill, MD Associate Director of Regulatory Affairs and Quality Assurance Clinical Trials Office.

1 Public Workshop on Risk Management Day 2 – Risk Management Programs Washington DC, April 10 International Society for Pharmacoepidemiology S. Pérez-Gutthann,

1 Dose Content Uniformity for Aerosol Products Wallace P. Adams, Ph.D. OPS/IO Advisory Committee for Pharmaceutical Science 13 March 2003 Rockville, MD.

Pharmaceutical Manufacturing Subcommittee of the ACPS Ajaz S. Hussain, Ph.D. ACPS Meeting October 22, 2002.

1 PTIT for DCU of OINDP: Approaches to Resolution of Identified Issues Wallace P. Adams, Ph.D. OPS/IO Advisory Committee for Pharmaceutical Science 21.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

ITFG/IPAC Collaboration Introduction OVERVIEW OF ITFG/IPAC COLLABORATION Presented by: Harris Cummings, PhD 26 April 2000 Rockville, MD.

ICH Quality Topics Update

1 Community-Based Care Readiness Assessment and Peer Review Overview Department of Children and Families And Florida Mental Health Institute.

Second Meeting of the FDA/ACPS Process Analytical Technology: Closing Remarks Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Sciences.

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy.

Bioequivalence Criteria Research Plan Stella G. Machado, Ph.D. Office of Biostatistics and the Replicate Design Technical Committee Advisory Committee.

Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, ACPS Meeting, Oct. 22, 2003 Office of Generic Drugs Research.

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

SEVESO II transposition and implementation: Possible approaches and lessons learned from member states and new member states SEVESO II transposition and.

ROAD MAP: Getting a Cancer Study Done at Jefferson Sylvia O’Neill, MD Associate Director of Regulatory Affairs and Quality Assurance Clinical Trials Office.

Orally Inhaled and Nasal Drug Products (OINDP) Subcommittee Report to the Advisory Committee for Pharmaceutical Sciences Rockville, Maryland November 15,

ITFG/IPAC Collaboration CMC Leachables and Extractables Technical Team ITFG/IPAC TECHNICAL TEAM: CMC LEACHABLES AND EXTRACTABLES Presented by: Kaushik.

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Dose Content Uniformity: Parametric Tolerance Interval Approach.

Office of Pharmaceutical Science OPS Center for Drug Evaluation and Research CDER FDA Food and Drug Administration HHS Health and Human Services 1 Advisory.

Parametric Tolerance Interval (PTI) Test for Delivered Dose Uniformity (DDU) for Orally Inhaled and Nasal Drug Products (OINDP) Michael Golden On behalf.

Pre-Investigational New Drug (pre-IND) Meeting with FDA

Presidential Department

Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.

Presentation transcript:

1 Process to Address Specifications for Delivered Dose Uniformity of Inhaled and Nasal Drug Products Presented by Robert O’Neill, Ph.D. Chair ACPS Working Group for DDU in OINDP 13 April 2004

2 Proposal: Joint Working Group under ACPS FDA/IPAC-RS Working Group –Populated by senior representatives from FDA and OINDP industry –Defined Process Identified objectives Establish communication mechanism Defined timelines, milestones and resolution target date –Overall WG Objective: To agree on mutually acceptable PTIT test for DDU for OINDP

3 Working Group Members Robert O’Neill, Ph.D. Chair (Director, Office of Biostatistics, Office of Pharmacoepidemiology and Statistical Science, CDER) Badrul Chowdhury, M.D., Ph.D. (Director, Division of Pulmonary Drug Products, Office of Drug Evaluation II, Office of New Drugs, CDER) Moheb Nasr, Ph.D. (Director, Office of New Drug Chemistry, CDER) Lawrence Yu, Ph.D. (Director for Science, Office of Generic Drugs) Michael Golden (Director, New Submissions North America, Global CMC Regulatory Affairs, GlaxoSmithKline) Kristi Griffiths, Ph.D. (Research Scientist, Global Statistical Sciences, Eli Lilly) Bo Olsson, Ph.D. (Scientific Adviser, Experimental Medicine, AstraZeneca) Dar Rosario (Director, Regulatory Affairs, Aradigm) Dennis Sandell, Ph.D. (Associate Principle Scientist, Analytical Development, AstraZeneca)

4 Objective of the Working Group Develop a mutually acceptable, standard DDU specification (test and acceptance criteria) for OINDP with a proposal to ACPS in 2004

5 Process Communication and Coordination –Communications Coordinated through Project Managers Agendas, minutes, meeting materials –Frequency of Meetings Monthly meetings at FDA, beginning in May 2004 May 2004 –Review ACPS Feedback –Identify technical expertise necessary to address »Statistical support »Clinical support »CMC support »Other –Technical Projects Leadership and project management for technical projects to assure resolution of issues in timely manner

6 Process (cont.) Timelines and Milestones –Status report to ACPS in October 2004 –Submit recommendation to ACPS by end 2004

7 Consensus Reached to Date Parametric tolerance interval approach is an improvement on current DDU test Concept requires refinement and further development to address regulatory requirements It is time to move forward and come to closure Working Group is formed to devote necessary resources and time to resolve (through data review and analysis, and development of appropriate statistical procedures)

8 Issues where Consensus is Needed Better understanding the difference between operating characteristic (OC) curves (difference between FDA and IPAC- RS called “gap”) Evaluation of simulated performance and actual performance Zero tolerance criterion Statistical details of the test design Applicability to non-normal distributions

9 Next Steps ACPS to endorse approach Working Group status report to ACPS in October 2004 Working Group to submit recommendation to ACPS by end 2004